Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib for Neuroinflammation in MDD
NCT04814355Phase 4Completed
- Sponsor
- Stony Brook University
- Start
- Aug 2018
- Primary completion
- Aug 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of celecoxib in major depressive disorder (MDD), sponsored by Stony Brook University. Started Aug 2018; status: completed.
02
Drugs
celecoxib
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04814355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814355.